A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy

Table 1 Weight Change with Terazosin

Study Type	N in study	Weight Change in Kg/ Number on therapy						Significance
		Total		Men		Women
		n	Δ	n	Δ	n	Δ
RCT
Deger [8]	174	100		49	+1.4	51	+1.2	p < .001 from baseline
Sperzel [27]	865	569		438	+0.9	131	+0.4	p < .05 against placebo
Observational ^*
Luther [28]^†	364	--	0 to +1.4					No statistical comparison
Mersey [29]	226	--	0 to +1.4					No statistical comparison
Withdrawal from therapy ^‡
Ruoff [12]	27	13	-1.3					'statistically significant' from baseline in both
Ruoff [12]	69	32		19	-1.6	13	-1.6

^*Observational studies were open label, multicenter, follow-up studies of hypertensive patients on terazosin. ^†Trial demonstrated significant hemodilution by laboratory exams. ^‡Two different RCTs are reported, in which responders to terazosin were randomized to withdrawal of therapy and monitored.

ISSN: 1745-6215